

# Jean-Jacques Grob

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714178/publications.pdf>

Version: 2024-02-01

95  
papers

31,585  
citations

44069

48  
h-index

48315

88  
g-index

97  
all docs

97  
docs citations

97  
times ranked

25281  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization of fast-growing melanomas. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 312-321.	1.2	11
2	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
3	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> <sup>V600E</sup> Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
4	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	2.8	17
5	Prognostic and predictive value of $\beta$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	2.8	18
6	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	13.7	236
7	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
8	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF</i> <sup>V600E</sup> -positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.6	6
9	Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9500-LBA9500.	1.6	7
10	Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with <i>TP53</i> <sup>WT</sup> Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9506-9506.	1.6	9
11	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1119-1132.	2.4	5
12	Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire. <i>Quality of Life Research</i> , 2021, 30, 1225-1231.	3.1	8
13	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	1.6	1
14	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
15	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	4.4	1
16	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
17	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
18	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 700-710.	1.5	12

#	ARTICLE	IF	CITATIONS
19	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Over	2.8	9
20	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	2.4	14
21	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
22	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1949-1956.	2.4	10
23	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) Tj ETQq1 1 0.784314 rgBT /Over IIIb study of trametinib in combination with dabrafenib. European Journal of Cancer, 2021, 154, 57-65.	2.8	9
24	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales De Dermatologie Et De Venereologie, 2021, 148, 145-155.	1.0	4
25	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. European Journal of Cancer, 2021, 156, S23-S24.	2.8	1
26	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. Blood, 2021, 138, 790-790.	1.4	4
27	Methotrexate for idiopathic chronic eczematous eruption of aging. European Journal of Dermatology, 2021, 31, 839-841.	0.6	0
28	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€“ Update 2019. European Journal of Cancer, 2020, 126, 159-177.	2.8	154
29	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	7.1	287
30	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438.	2.4	59
31	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Advances, 2020, 4, 5203-5214.	5.2	18
32	Adjuvant nivolumab versus ipilimumab in resected stage IIIâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	10.7	330
33	The evolving field of Dermatoâ€“oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDVâ€“UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
34	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 2020, 38, 3925-3936.	1.6	192
35	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. European Journal of Cancer, 2020, 133, 94-103.	2.8	13
36	Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. European Journal of Cancer, 2020, 135, 52-61.	2.8	24

#	ARTICLE	IF	CITATIONS
37	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
38	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 2020, 13, 457-467.	2.7	11
39	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. European Journal of Cancer, 2020, 128, 60-82.	2.8	131
40	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. European Journal of Cancer, 2020, 128, 83-102.	2.8	181
41	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics “ Update 2019. European Journal of Cancer, 2020, 126, 141-158.	2.8	133
42	Anti-N-methyl-D-aspartate receptor encephalitis during treatment with adalimumab for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e591-e593.	2.4	3
43	SARS-CoV-2 infection presenting as a febrile rash. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e304-e306.	2.4	59
44	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	2.8	132
45	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	10.7	812
46	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	27.0	2,484
47	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncology, The, 2019, 20, 1083-1097.	10.7	611
48	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	2.8	64
49	Adverse events 2.0”Let us get SERIOs. European Journal of Cancer, 2019, 112, 29-31.	2.8	19
50	Diabetes and Blood Glucose Disorders Under Anti-PD1. Journal of Immunotherapy, 2018, 41, 232-240.	2.4	27
51	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	27.0	1,441
52	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. JAMA Oncology, 2018, 4, e180077.	7.1	304
53	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492.	10.7	1,089
54	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs, 2018, 78, 1197-1209.	10.9	34

#	ARTICLE	IF	CITATIONS
55	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	10.7	131
56	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018, 28, 775-783.	0.6	16
57	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
58	Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <i>Annals of Oncology</i> , 2017, 28, 1137-1144.	1.2	94
59	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
60	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
61	Macrophage activation syndrome: A new complication of checkpoint inhibitors. <i>European Journal of Cancer</i> , 2017, 77, 88-89.	2.8	31
62	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
63	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
64	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	18.7	1,032
65	Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. <i>European Journal of Cancer</i> , 2017, 84, 44-54.	2.8	67
66	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017, 2, e000203.	4.5	15
67	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017, 136, 2085-2087.	1.6	364
68	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	7.1	131
69	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	2.8	76
70	Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. <i>PLoS ONE</i> , 2017, 12, e0176080.	2.5	8
71	Risk factors of fast growing melanomas in a French prospective cohort.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21042-e21042.	1.6	0
72	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140

#	ARTICLE	IF	CITATIONS
73	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	1.2	21
74	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	10.7	266
75	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
76	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
77	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	30.5	417
78	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq0 0 0 rgBT /Overlock 10 Tf	16.7	1,093
79	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	1.6	445
80	Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study. <i>Journal of Investigative Dermatology</i> , 2015, 135, 67-75.	0.7	307
81	On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2014, 25, 2086-2091.	1.2	72
82	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014, 120, 2016-2024.	4.1	19
83	Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. <i>European Journal of Cancer</i> , 2014, 50, 1120-1124.	2.8	15
84	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , 2014, 25, 1428-1436.	1.2	45
85	On-demand Gamma Knife combined with BRAF inhibitors for the treatment of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9083-9083.	1.6	0
86	Learning from examples to automatically cluster pigmented skin lesions. , 2013, , .		1
87	Evidence of a Limited Intra-Individual Diversity of Nevi: Intuitive Perception of Dominant Clusters Is a Crucial Step in the Analysis of Nevi by Dermatologists. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2355-2361.	0.7	23
88	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 358-365.	13.7	2,691
89	Le dermatologue et le m�lanome. D�t�mo�n� venons-nous? O� sommes-nous? O� allons-nous?. <i>Annales De Dermatologie Et De Venereologie</i> , 2012, 139, B18-B19.	1.0	0
90	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	4.4	563

#	ARTICLE	IF	CITATIONS
91	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	27.0	4,074
92	Cognitive training with photographs as a new concept in an education campaign for self-detection of melanoma: a pilot study in the community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1099-1103.	2.4	12
93	Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: A series of 106 patients without whole-brain radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 809-816.	0.8	90
94	Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: A randomized study. <i>International Journal of Cancer</i> , 2006, 118, 2276-2280.	5.1	76
95	Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 1118-1125.	1.6	439